About PNH

PNH, a progressive and life-threatening disease, is a result of increased hemolysis, or the destruction of red blood cells.2,3 Chronic hemolysis is the underlying mechanism in PNH that leads to a variety of major health problems associated with the disease, such as thrombosis (formation of blood clots), pulmonary hypertension and damage or failure of organs such as the brain, liver, gastro-intestinal system and kidneys.2-5 Patients also experience a variety of symptoms that can interfere with quality of life, including abdominal pain, difficulty swallowing, poor physical function, shortness of breath, erectile dysfunction and debilitating fatigue.5,6

The frequency and severity of these symptoms varies widely among patients with PNH.2 The effects of hemolysis can be subtle. However, researchers are learning that all PNH patients have some level of excessive hemolysis, and the long-term consequences can be unpredictable, sudden and potentially deadly.7

Effects of Hemolysis



IMPORTANT SAFETY INFORMATION

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

Soliris® increases the risk of meningococcal infections

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).